Orchestra BioMed (US:OBIO) ZACKS·2026-03-12 14:35分组1 - Orchestra BioMed Holdings, Inc. reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of a loss of $0.38 per share, representing an earnings surprise of +168.87% [1] - The company posted revenues of $30.92 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3,813.54%, compared to revenues of $0.25 million a year ago [2] - The stock has increased by approximately 10.8% since the beginning of the year, while the S&P 500 has declined by 1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $0.78 million, and for the current fiscal year, it is -$1.58 on revenues of $3.28 million [7] - The Medical - Biomedical and Genetics industry is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for Orchestra BioMed Holdings, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]